Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
Revenues
Royalty and licensing revenue	$ 5,097,595	$ 800,000
Treatment investment revenue	4,800,000	750,000
Revenues	9,897,595	1,550,000
Operating expenses
General and administrative	15,571,080	6,034,520
Research and development	1,747,077	2,414,973
Selling expenses	317,917	0
Total operating expenses	17,636,074	8,449,493
Loss from operations	(7,738,479)	(6,899,493)
Other income (expense)
Interest expense, net	(11,890)	(28,232)
Loss on foreign exchange	(63,887)	(110,148)
Total other income (expense)	(75,777)	(138,380)
Loss before provision for income taxes	(7,814,256)	(7,037,873)
Provision for income taxes	0	0
Net loss	$ (7,814,256)	$ (7,037,873)
Loss per share of common stock:
Basic and diluted	$ (4.09)	$ (3.88)
Weighted average common stock outstanding
Basic and diluted	1,910,489	1,813,069